CARB-X receives additional US$ 370m from US Government and Wellcome Trust
CARB-X (part of Boston University) announces the renewal of its support from Wellcome Trust, a worldwide charitable foundation, and the U.S. Department of Health and Human Services (HHS) BARDA, the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within HHS, will spend US$20 million initially, and up to US$300 million over a 10 year span to progress the existing portfolio and launch rounds of new funding. NIAID, the U.S. National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH) in HHS, will provide in-kind services by giving access to different preclinical services for the development of new products. The Wellcome Trust will make available over the course of three years a total of up to US$70 million, which is part of its continued commitment to combat the fight against antimicrobial resistances. CARB-X had been launched in 2016 through an initial sum of $355 million by both BARDA and Wellcome Trust. Thus, the additional funding announced today builds on the previous success.
Kevin Outterson, Executive Director of CARB-X and Professor of Law at Boston University said: “We are grateful for the leadership and commitment demonstrated by BARDA and Wellcome in addressing the global challenge of antimicrobial resistant bacteria. We now know that antimicrobial resistance (AMR) kills more people each year than HIV or malaria, and a similar number to TB. AMR is a top-tier global killer. With today’s funding announcements, CARB-X will continue to invest to support early-stage research and development (R&D) for new antibacterial therapies, preventatives, and diagnostics.”
CARB-X funders other than BARDA, NIAID and Wellcome, include the U.K. and German governments (the Global AMR Innovation Fund and the Federal Ministry of Education and Research), and the Bill & Melinda Gates Foundation. Their original agreements end in 2022 and 2023 and are not yet up for renewal.
“Antibiotic-resistant infections not only pose a growing public health crisis but also complicate the response to public health emergencies. We see a wealth of valuable basic AMR research and early discovery stemming from NIAID and other critical organizations around the globe. Alongside our CARB-X global partners, we are helping transform this research into preclinical and clinical candidates that, with potential support from BARDA and other late-stage funders, can be further developed into approved products that can help prevent and treat bacterial infections, and ultimately, save lives,” said Gary Disbrow, PhD, Director of BARDA.
CARB-X has received since its inception more than US$500 m and invested US$361 m of this non-dilutive funding to progress a total of 92 innovative projects in 12 different countries.